Clinical Trial ProgressGH001 Phase 2b trial data in treatment-resistant depression shows promise, potentially enhancing the drug's profile and investor confidence.
Intellectual PropertyThe grant of patent EP3927337 by the European Patent Office represents a significant step in protecting GH Research's proprietary developments.
Regulatory MilestonesGH Research's engagement with the FDA and the upcoming meeting to discuss GH001 could lead to resolution of the clinical hold, positively influencing the stock.